Last reviewed · How we verify
MMI
MMI is a selective monoamine oxidase B (MAO-B) inhibitor.
MMI is a selective monoamine oxidase B (MAO-B) inhibitor. Used for Parkinson's disease.
At a glance
| Generic name | MMI |
|---|---|
| Sponsor | Xiao-Ming Mao |
| Drug class | MAO-B inhibitor |
| Target | MAO-B |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
By inhibiting MAO-B, MMI reduces the breakdown of dopamine in the brain, increasing its availability and potentially alleviating symptoms of Parkinson's disease.
Approved indications
- Parkinson's disease
Common side effects
- Orthostatic hypotension
Key clinical trials
- Mindfulness Meditation Intervention Study (NA)
- Targeting the Hip Abductors to Reduce Falls in Older Veterans Through A Virtual Multimodal Balance Intervention (NA)
- Inhaled Oxytocin and HPA Axis Reactivity (PHASE2)
- A Clinical Follow-up Study on Drug Therapy for Graves' Disease Patients in China
- Phase 2 Study to Assess Efficacy & Safety of WP1302 Prevent Relapse of MMI w/Draw in Subj. w/ Graves' dz (PHASE2)
- Examining Effects of Holistic School Enrichment Programs (NA)
- A Clinical Study of Hyperthyroidism in Children
- Iodine Supplementation in Graves' Hyperthyroidism (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MMI CI brief — competitive landscape report
- MMI updates RSS · CI watch RSS
- Xiao-Ming Mao portfolio CI